Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=-start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-start_date" }, "data": [ { "type": "Grant", "id": "15763", "attributes": { "award_id": "1RF1NS138437-01A1", "title": "Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32579, "first_name": "WILLIAM PATRICK", "last_name": "DALEY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-11", "end_date": "2029-07-31", "award_amount": 2549080, "principal_investigator": { "id": 31999, "first_name": "Sarah Elizabeth", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2631, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 increases the risk of vascular contributions to cognitive impairment and dementia (VCID). VCID is one of the most prevalent forms of dementia, so the potential public health impact of the COVID-19 pandemic on future VCID is substantial. However, the mechanisms by which COVID-19 modifies VCID are unknown. Identifying mechanisms that regulate how prior COVID-19 influences the brain endothelial cell response to vascular stress is important. Here, we provide preliminary evidence that COVID-19 decreases resistance to VCID by weakening the blood-brain barrier (BBB). This is accompanied by cerebrovascular inflammation. This grant will test the novel mechanism that SARS-CoV-2 infection accelerates VCID by suppressing cerebrovascular Wnt/β-catenin signaling. In Aim 1, we determine how prior SARS-CoV-2 infection influences BBB permeability and cognition upon subsequent vascular insult, by genetic and epigenetic modification. In Aim 2 we use endothelial-targeted genetic interventions to assess the contribution of Wnt/β- cat targets to resistance to post-infectious VCID. In Aim 3, we ask whether established post-infectious VCID can be reversed by increasing cerebrovascular Wnt/β-catenin. These studies could lead to novel approaches to identify individuals at high risk for VCID and novel potential therapeutic strategies to mitigate the impact of prior infection on the development of dementia.", "keywords": [ "2019-nCoV", "ATAC-seq", "Acceleration", "Acute", "Blood - brain barrier anatomy", "Blood Vessels", "Blood brain barrier dysfunction", "COVID-19", "COVID-19 pandemic effects", "Cells", "Cerebrovascular system", "Clinic", "Cognition", "Critical Pathways", "Data", "Dementia", "Development", "Endothelial Cells", "Endothelium", "Engineering", "Epigenetic Process", "Extravasation", "Functional disorder", "Future", "Genes", "Genetic", "Goals", "Grant", "High Fat Diet", "Human", "Hypertension", "Impaired cognition", "Individual", "Infection", "Inflammation", "Inflammatory", "Knowledge", "Ligands", "Modification", "Mus", "Pathogenicity", "Pathway interactions", "Pattern", "Pericytes", "Permeability", "Phenotype", "Prevention", "Public Health", "Recording of previous events", "Recovery", "Research", "Resistance", "Respiratory Tract Infections", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Signal Transduction", "Testing", "Therapeutic", "Translating", "Vascular Dementia", "Viral", "beta catenin", "blood-brain barrier permeabilization", "brain endothelial cell", "cerebrovascular", "gene therapy", "high risk", "in vivo", "inhibitor", "macromolecule", "mouse model", "neuroinflammation", "neurotoxic", "novel", "novel strategies", "post SARS-CoV-2 infection", "post-pandemic", "prevent", "programs", "promote resilience", "respiratory", "response", "small molecule", "therapeutic target", "transcriptome sequencing", "vascular cognitive impairment and dementia", "vascular stress" ], "approved": true } }, { "type": "Grant", "id": "15754", "attributes": { "award_id": "1U01AI186939-01", "title": "Mitigation of multi-organ delayed effects of acute radiation exposure (DEARE) with ACE2 agonist diminazene aceturate.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 32816, "first_name": "CARMEN I", "last_name": "RIOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-11", "end_date": "2030-07-31", "award_amount": 546000, "principal_investigator": { "id": 32817, "first_name": "Heather A", "last_name": "Himburg", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2624, "ror": "", "name": "MEDICAL COLLEGE OF WISCONSIN", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "With the advent of hematopoietic growth factors for mitigation of acute radiation syndrome (ARS), victims of nuclear or radiological events will be more likely to survive ARS but also at greater risk for the development of a range of late multi-organ toxicities collectively referred to as the delayed effects of acute radiation exposure (DEARE). To date, there are no FDA-approved medical countermeasures (MCMs) for the treatment of DEARE. This application to RFA-AI-23-059 (Development of Candidate Radiation/Nuclear MCMs) proposes to address this unmet need and will focus on the unmet need for MCMs against two life-threatening subsyndromes of DEARE: radiation pneumonitis and nephropathy. Here, we propose to screen three candidate MCMs which target the non-canonical, alternative renin angiotensin system (RAS). As a counterbalance to the canonical RAS, the alternative RAS has broad tissue-protective function by promoting vasodilation, reducing inflammation, and reducing fibrosis. For these reasons, several recent and ongoing clinical trials are evaluating alternative RAS activators for the treatment of severe COVID-19. Data from our lab and others also supports the potential for alternative RAS activation in the treatment of radiation toxicities. Our laboratory has shown diminazene aceturate (DIZE) a small molecule agonist of the alternative RAS pathway promotes survival in rat models of ARS and DEARE. Important to this application, DIZE treatment also mitigated injury to the lung and kidney as evidenced by improved survival during the sub-syndromes of lung and kidney DEARE. Based on these data, we hypothesize the alternative RAS pathway can be targeted pharmacologically to mitigate radiation-induced multi-organ DEARE. Here, we propose a stepwise approach to targeting three key players in the alternative RAS pathway: angiotensin converting enzyme 2 (ACE2), Ang(1-7), and the Mas receptor (MasR). Each Aim of this application will target one of these players using the following lead candidate therapies: DIZE (ACE2 activator), TXA127 (synthetic Ang(1-7)), and BIO101 (MasR activator). We will evaluate the efficacy of the candidate MCMs in an established rat DEARE model which recapitulates the anticipated human sequelae of acute and delayed toxicities. For each candidate MCM, the primary outcome measure will be mitigation of all-cause mortality, which is the clinically relevant endpoint for FDA approval under the Animal Rule.", "keywords": [ "ACE2", "Acceleration", "Acute", "Acute Respiratory Distress Syndrome", "Address", "Adult", "Agonist", "Anti-Inflammatory Agents", "Antiinflammatory Effect", "Antioxidants", "Binding", "Body System", "Bone Marrow", "COVID-19", "Clinical Research", "Clinical Trials", "Data", "Development", "Dose", "Exposure to", "FDA approved", "Fibrosis", "G-Protein-Coupled Receptors", "Generations", "Goals", "Hematopoietic", "Hematopoietic Cell Growth Factors", "Homeostasis", "Human", "Hypoxia", "In Vitro", "Inflammation", "Injury", "Investigation", "Ischemic Stroke", "Kidney", "Kidney Diseases", "Laboratories", "Life", "Lung", "Modeling", "Nuclear", "Nuclear Accidents", "Oral Administration", "Organ", "Outcome Measure", "Pathway interactions", "Peptide Signal Sequences", "Phase I/II Clinical Trial", "Play", "Population", "Radiation", "Radiation Accidents", "Radiation Injuries", "Radiation Pneumonitis", "Radiation Toxicity", "Radiation exposure", "Rattus", "Recovery", "Renin-Angiotensin System", "Reproducibility", "Respiratory Failure", "Risk", "Rodent Model", "Signal Transduction", "Testing", "Therapeutic Uses", "Time", "Tissues", "Toxic effect", "Vasodilation", "Vasodilator Agents", "Work", "animal rule", "clinical investigation", "clinically relevant", "efficacy evaluation", "experience", "improved", "in vivo Model", "irradiation", "lead candidate", "mass casualty", "medical countermeasure", "mortality", "multiorgan injury", "nuclear countermeasure", "pharmacologic", "pre-clinical", "preclinical study", "primary outcome", "programs", "protective effect", "radiation mitigation", "radiation mitigator", "receptor", "response", "severe COVID-19", "small molecule", "stroke patient", "subcutaneous", "therapeutic target" ], "approved": true } }, { "type": "Grant", "id": "15797", "attributes": { "award_id": "1R01HL176849-01A1", "title": "Pathogenic mechanisms of chronic lung sequelae following respiratory viral infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32514, "first_name": "EMMANUEL FRANCK", "last_name": "MONGODIN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-10", "end_date": "2029-05-31", "award_amount": 754729, "principal_investigator": { "id": 32886, "first_name": "John F", "last_name": "Alcorn", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32525, "first_name": "Lianghui", "last_name": "Zhang", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has brought the world’s attention on respiratory viral infections. It is not a question of if another respiratory viral pandemic will arise, but rather when. The diversity of viral pathogens presents a tremendous challenge for designing virus targeted preventions and therapeutics. However, respiratory viruses cause similar lung injury that drives morbidity and mortality. A focus on host mediated lung injury pathways in this context is warranted, as there is potential for therapeutic interventions that would be effective across a range of respiratory viral infections. The COVID-19 pandemic has drawn attention to a poorly characterized phenotype of persistent lung inflammation that lasts well beyond clearance of live virus. Long-COVID and long-Flu are clinical diagnoses that lack an understanding of the molecular underpinnings of disease. In this application, we focus on understanding the mechanism by which respiratory viral infection causes lasting tissue damage covering antigen persistence, presentation, and a positive feedback inflammatory cell network. We propose that the persistent presence of viral antigen in pulmonary endothelial cells is a major driver for the prolonged activation of CD8+ T cells, consequently leading to chronic pulmonary sequelae, through reinforced interaction of CD8+ TRM cells and pro-inflammatory macrophages. This hypothesis will be tested in two Aims: 1) we will investigate the contribution of persistent activation of CD8+ T cells by pulmonary endothelial cells to the development of chronic pulmonary sequelae, and 2) we will interrogate the T cell and macrophage inflammatory axis in persistent inflammation during recovery from respiratory viral infection. To examine these pathways, we will employ the SARS-CoV-2 and influenza virus mouse models, and we will confirm findings using tissue from human patient transbronchial biopsies. Discovery of causative host inflammatory pathways that are critical to post-viral lung sequelae would provide pre-clinical evidence to support clinical trials. If pathogenic mechanisms are indeed similar between multiple respiratory viruses, then host-directed therapeutics would potentially have a tremendous impact. Currently, there are no specific therapies indicated for the treatment of post-viral lung inflammation.", "keywords": [ "2019-nCoV", "Acute", "Antibodies", "Antigen Presentation", "Antigen-Presenting Cells", "Antigens", "Attention", "Automobile Driving", "Biopsy", "Biopsy Specimen", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19 pandemic", "Cells", "Chronic", "Clinical Trials", "Coronavirus Infections", "Critical Pathways", "Data", "Development", "Disease", "Economic Burden", "Endothelial Cells", "Endothelium", "Epidemic", "Exudate", "Feedback", "Fibrosis", "Frustration", "Functional disorder", "Goals", "Human", "IFNGR1 gene", "Immune", "In Vitro", "Infection", "Inflammation", "Inflammatory", "Influenza", "Influenza A Virus H1N1 Subtype", "Interferon Type II", "Intervention", "Knock-out", "Long COVID", "Lung", "Lymphocyte", "Lymphoid", "MHC Class I Genes", "Macrophage", "Mediating", "Metabolism", "Molecular", "Morbidity - disease rate", "Mus", "Myelogenous", "Pathogenesis", "Pathogenicity", "Pathologic", "Pathway interactions", "Patients", "Phenotype", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prevention", "Production", "Proteins", "Public Health", "Pulmonary Inflammation", "Recovery", "Resolution", "Role", "SARS-CoV-2 infection", "Signal Transduction", "Source", "T-Lymphocyte", "T-cell inflamed", "Testing", "Therapeutic", "Therapeutic Intervention", "Tissues", "Upper Respiratory Infections", "Viral", "Viral Antigens", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "Work", "beta-2 Microglobulin", "clinical diagnosis", "coronavirus pandemic", "cytokine", "design", "effector T cell", "experience", "flu", "human tissue", "influenza infection", "influenzavirus", "lung injury", "lung microvascular endothelial cells", "lung repair", "mortality", "mouse model", "neutralizing antibody", "novel", "pathogenic virus", "pharmacologic", "polarized cell", "pre-clinical", "pulmonary", "pulmonary vascular cells", "repaired", "respiratory", "respiratory virus", "restoration", "single-cell RNA sequencing", "socioeconomics", "spatial transcriptomics", "tissue resident memory T cell", "viral pandemic" ], "approved": true } }, { "type": "Grant", "id": "15768", "attributes": { "award_id": "75N92023D00011-0-759202500001-1", "title": "COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 3 - AUGUST 10, 2025 - AUGUST 9, 2026", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2025-08-10", "end_date": "2026-08-09", "award_amount": 9292344, "principal_investigator": { "id": 32839, "first_name": "LEE S", "last_name": "NEWMAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2636, "ror": "", "name": "NATIONAL JEWISH HEALTH", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Genetic Epidemiology of COPD (COPDGene) is a multi-site longitudinal cohort study of current and former smokers to better understand risk factors, natural history, and genetic contributions of chronic obstructive pulmonary disease (COPD) as well as other smoking-related diseases. The purpose of this acquisition is to fund a 15-year follow-up in-person clinical visit (Visit 4) of this cohort, to be re-enrolled from approximately 19 active Clinical Study Centers. A Visit 4 of COPDGene subjects is needed to identify clinical, physiological, imaging, and Omics determinants of COPD and other disease progression in elderly subjects, to assess the impact of COVID-19 on COPD and other disease progression, and to discover determinants of severe COPD development in subjects with preserved ratio, impaired spirometry (PRISm). The acquisition will also support the maintenance of previously collected data and biospecimens, regulatory oversight of the study, and analysis of study data and study biospecimens. The goal of COPDGene is to use extensive longitudinal imaging, physiology, and Omics molecular data in combination with genetics in the COPDGene cohort to identify high-risk subgroups with distinct diagnostic, prognostic, and therapeutic implications. COPDGene has been funded for 15 years through grants and cooperative agreements awarded by NHLBI to National Jewish Health and Brigham and Women’s Hospital. Grant applications for the three Phases of COPDGene [Phase 1: baseline visit (“Visit 1”); Phase 2: five year follow-up (“Visit 2”); Phase 3: ten year follow-up (“Visit 3”)] were all submitted to the parent NIH R01 Funding Opportunity Announcement. Study investigators originally recruited 10,198 current or former smokers in Phase 1. Including nonsmoking controls from both Phase 1 and Phase 2, COPDGene has recruited a total 10,718 subjects all of whom have been extensively phenotyped clinically and radiologically. Additional data collected on these participants include whole genome sequencing as well as RNA sequencing, proteomics, metabolomics, and DNA methylation data from collected blood samples. Investigators have published more than 450 publications, the vast majority of which were peer-reviewed, using COPDGene data. COPDGene also serves as a parent study for many ancillary studies, using public or private funding, a subset of which have collected additional data on all or a subset of participants. COPDGene is overseen by an NHLBI-convened Observational Study Monitoring Board (OSMB). The Visit 4 (15-year follow-up) evaluations will include, where possible, lung function tests (spirometry), questionnaires (including COVID-19 assessment), chest computerized tomography (CT), other functional assessments (e.g., six minute walk distance), and collection and storage of biospecimens from 3,500 of the original 10,718 COPDGene subjects. In addition, this acquisition will support continuation of semi-annual long-term follow-up of the COPDGene cohort and other contact with the cohort as needed, oversight of clinical sites and human subjects protection, maintenance of the database and biobank, continued coordination with NIH and NHLBI data resources, activities relevant to the data management and sharing plan, analysis of data, travel to meetings, and publication costs.", "keywords": [ "Address", "Adverse event", "Ancillary Study", "Annual Reports", "Applications Grants", "Archives", "Area", "Award", "Bioinformatics", "Biological Markers", "Biological Specimen Banks", "Blood specimen", "Bronchodilator Agents", "COVID-19", "COVID-19 impact", "Cause of Death", "Certification", "Cessation of life", "Characteristics", "Chest", "Chronic Obstructive Pulmonary Disease", "Clinical", "Clinical Data", "Clinical Research", "Clinical/Radiologic", "Collaborations", "Collection", "Communication", "Communities", "Compensation", "Computer Security", "Contractor", "Contracts", "DNA Methylation", "Data", "Data Analyses", "Data Coordinating Center", "Data Science", "Data Security", "Data Set", "Databases", "Development", "Diagnostic", "Diffusion", "Disease Progression", "Documentation", "Educational workshop", "Elderly", "Electronics", "Enrollment", "Ensure", "Epidemiology", "Evaluation", "Event", "Funding", "Funding Opportunities", "Future", "Genes", "Genetic", "Genomics", "Goals", "Grant", "Health", "Hospitals", "Image", "Impairment", "Information Systems", "Institutional Review Boards", "International", "Internet", "Jews", "Journals", "Laboratories", "Link", "Long-term Follow-up", "Longitudinal cohort study", "Maintenance", "Manuscripts", "Measures", "Medical History", "Metadata", "Methods", "Molecular", "Monitor", "Names", "National Heart Lung and Blood Institute", "Natural History", "Observational Study", "Outcome", "Oxygen", "Parents", "Participant", "Peer Review", "Persons", "Phase", "Physical Performance", "Physiological", "Physiology", "Policies", "Privatization", "Procedures", "Proteomics", "Protocols documentation", "PubMed", "Publications", "Publishing", "Pulmonary Emphysema", "Pulmonary function tests", "Quality Control", "Quality of life", "Questionnaires", "Recommendation", "Reporting", "Research", "Research Personnel", "Resolution", "Resources", "Risk Factors", "SARS-CoV-2 infection", "Scanning", "Schedule", "Scientist", "Site", "Specific qualifier value", "Spirometry", "Standardization", "Subgroup", "Support Contracts", "System", "Teleconferences", "Telephone", "Testing", "Therapeutic", "Time", "Tobacco use", "Training", "Trans-Omics for Precision Medicine", "Travel", "U-Series Cooperative Agreements", "United States National Institutes of Health", "Update", "Vaccination", "Visit", "Walking", "Woman", "Work", "X-Ray Computed Tomography", "adjudication", "biobank", "catalyst", "clinical ce" ], "approved": true } }, { "type": "Grant", "id": "15783", "attributes": { "award_id": "1R01AI188944-01A1", "title": "PRECISE: accessible sample-to-answer RT-PCR detection of hepatitis C infection from whole blood", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32845, "first_name": "JULIE", "last_name": "DYALL", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-08", "end_date": "2030-07-31", "award_amount": 575356, "principal_investigator": { "id": 32862, "first_name": "Samuel K", "last_name": "Sia", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2647, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal is in response to NOSI NOT-AI-23-001, which calls for new point-of-care HCV diagnostics. Most of global HCV burden is concentrated in low- and middle-income countries (LMICs), but the U.S. has witnessed a steady increase in infection rates in the past decade, with an estimated 140,000 new cases annually. Whereas direct-acting antivirals (DAAs) can over 95% of HCV-infected individuals, and are becoming more accessible, about 40% of infected people are unaware of their status. The current two-step diagnostic process requires an initial antibody screen followed by an expensive and time-consuming RNA test to confirm active infection. This cumbersome workflow requires multiple office visits for patients, resulting in delays in treatment initiation and significant patient follow-up loss. Our lab has been developing plasmonic-based thermocycling into a clinically useful method for fast multiplexed RT-PCR at the POC. In this approach, heating is achieved not externally via the Peltier effect, but rather internally via infrared excitation of nanoparticles; as a result, the heating is rapid, and powered with low- power robust optical components. We have gathered substantial preliminary data to validate the premise of this approach to work on clinical specimens (saliva and nasal swabs); the results (published in Nature Nanotechnology, 2022) showed the ability, within 25 minutes from sample to result, to detect SARS-CoV-2 with high sensitivity and specificity. Moreover, even in the presence of the plasmonic nanoparticles, we showed that real-time qPCR could be performed with accurate quantitative determinations of cycle threshold (Ct) values. This capability for sample-to-result analysis is faster than traditional PCR approaches using Peltier heating, and the instrumentation using readily available optics renders the approach suitable for community testing sites where rapid and accurate results are sought. This proposal integrates plasmonic PCR with plasma filtration (starting with whole blood) and magnetic bead-based nucleic-acid extraction (a technique we recently published called PRECISE, Lab Chip, 2024). The proposed combined method, PRECISE plasmonic PCR, takes advantage of special nanoparticles to facilitate a seamless sample-to-result workflow for the end user, suitable for the target community health settings to facilitate HCV diagnosis in a single patient visit to enable on-the-spot treatment. The target metrics would be the best in class among HCV nucleic-acid tests, meeting all of the criteria in the target product profile recommended by the NOSI for an “optimal” test except for the 15-minute turnaround time (our target is 30 minutes), and surpassing all “minimal” targets. The target metrics include cost considerations.", "keywords": [ "Accountability", "Anti-viral Agents", "Antibodies", "Benchmarking", "Biological Assay", "Blood", "Blood specimen", "COVID-19 detection", "Caring", "Clinic", "Clinical", "Collection", "Communities", "Community Health", "Consumption", "Data", "Decentralization", "Detection", "Devices", "Diagnosis", "Diagnostic", "Filtration", "HCV infection", "Health Care Surveys", "Health Personnel", "Heating", "Hepatitis C virus", "India", "Individual", "Infection", "Liver", "Magnetism", "Malignant neoplasm of liver", "Methods", "Microfluidics", "Nanotechnology", "Nature", "New Jersey", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Office Visits", "Optics", "Patients", "Persons", "Phase", "Plasma", "Preparation", "Primary Care", "Process", "Publishing", "RNA", "Recommendation", "Research Institute", "Reverse Transcriptase Polymerase Chain Reaction", "Saliva", "Sampling", "Sensitivity and Specificity", "Site", "Specimen", "Spottings", "Techniques", "Technology", "Temperature", "Testing", "Time", "Training", "Tube", "United States", "Vendor", "Visit", "Whole Blood", "Work", "cost", "cost effective", "detection limit", "detection platform", "follow-up", "high risk", "improved", "infection rate", "innovation", "instrumentation", "low and middle-income countries", "magnetic beads", "meetings", "mortality", "nanoGold", "nanoparticle", "nanoshell", "nasal swab", "novel", "operation", "plasmonics", "point of care", "point of care testing", "response", "screening uptake", "skills", "usability", "user-friendly", "viral detection" ], "approved": true } }, { "type": "Grant", "id": "15774", "attributes": { "award_id": "1R44AI191836-01", "title": "Development of a monoclonal therapy for neonatal herpes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32845, "first_name": "JULIE", "last_name": "DYALL", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-08", "end_date": "2026-07-31", "award_amount": 248531, "principal_investigator": { "id": 32846, "first_name": "Michael H", "last_name": "Pauly", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32847, "first_name": "Kevin John", "last_name": "Whaley", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2641, "ror": "", "name": "ZABBIO, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Neonatal infections caused by herpes simplex virus 1 or 2 (HSV-1, HSV-2) result in significant morbidity and mortality. Current medical treatment of neonatal HSV infections (nHSV) is limited to small molecule antivirals such as acyclovir, but even with high dose treatment, mortality subsequent to disseminated disease remains high (30%), and central nervous system (CNS) disease is associated with ∼70% neurological morbidity and 25% mortality. Monoclonal antibodies (mAbs) offer a class of intervention that provides immediate protection and a well-established development path, with over 200 mAb products licensed by U.S. and European regulatory bodies. Passive immunization with mAbs has been shown to be effective against a wide variety of infectious agent, with mAbs against Ebola virus, SARS-CoV-2, and Respiratory Syncytial Virus (RSV) approved by the FDA. Members of the ZabBio team have previously advanced 3 mAb products to clinical trials, including one which contained the broadly neutralizing HSV mAb, HSV8, which is the focus of this product development Fast Track SBIR proposal for neonatal HSV infection. More recently, ZabBio scientists have collaborated with Drs. Margaret Ackerman and David Leib (Dartmouth) who have demonstrated the utility of HSV8 in a mouse model of nHSV. These data support the hypothesis that HSV8 may be a useful clinical intervention for nHSV in humans. Phase 1 of this proposal contains 2 aims: 1) Assess the neutralization potency of HSV8 against a panel of HSV-1 and HSV-2 isolates from neonatal herpes patients; 2) Test whether HSV8 selects for HSV-1 and HSV-2 escape mutants. These two aims will result in a rigorous Go/No decision for proceeding to Phase 2. In Phase 2, the proposal transitions to traditional product development with 3 aims: 1) Manufacture HSV8 under cGMP in the Nicotiana benthamiana based Rapid Protein Production Platform (RP3) system; 2) Submit pre-IND to FDA; 3) Perform IND-enabling pharmacology/toxicology studies. This work scope will culminate in an Investigational New Drug (IND) submission.", "keywords": [ "2019-nCoV", "Acyclovir", "Adult", "Anti-viral Agents", "Atopobium vaginae", "Biological Assay", "Central Nervous System Diseases", "Chemistry", "Clinical", "Clinical Pathways", "Clinical Treatment", "Clinical Trials", "Collaborations", "Congenital herpes simplex", "Cyclic GMP", "Data", "Development", "Disease", "Dose", "Ebola virus", "Escape Mutant", "European", "FDA approved", "Feedback", "Film", "Herpesvirus 1", "Human", "Human Herpesvirus 2", "Incubated", "Infectious Agent", "Intervention", "Investigational Drugs", "Licensing", "Medical", "Monoclonal Antibodies", "Monoclonal Antibody Therapy", "Morbidity - disease rate", "Neonatal", "Neurologic", "Nicotiana", "Passive Immunization", "Patients", "Pharmaceutical Preparations", "Pharmacology and Toxicology", "Phase", "Phase I Clinical Trials", "Predisposition", "Production", "Proteins", "Research Design", "Respiratory syncytial virus", "Rodent", "Running", "Safety", "Scientist", "Simplexvirus", "Small Business Innovation Research Grant", "System", "Techniques", "Testing", "Tissues", "Toxicokinetics", "Virus", "Work", "cross reactivity", "efficacy study", "manufacture", "member", "monoclonal antibody production", "mortality", "mouse model", "mutant", "neonatal infection", "neonatal mice", "phase 1 study", "product development", "small molecule", "trial planning", "vaginal microbicide", "virology" ], "approved": true } }, { "type": "Grant", "id": "15780", "attributes": { "award_id": "1R01CA293884-01A1", "title": "The impact of dyadic processes on smoking and cigarette craving: An experimental investigation of romantic partners and smoking friends", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32857, "first_name": "REBECCA", "last_name": "FERRER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-07", "end_date": "2029-07-31", "award_amount": 2202321, "principal_investigator": { "id": 32858, "first_name": "Amanda", "last_name": "Forest", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32859, "first_name": "MICHAEL Andrew", "last_name": "SAYETTE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2644, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Smoking is the leading preventable cause of cancer and mortality in the US, with Covid hitting smokers especially hard. Quitting is difficult (and smoking increased during Covid), yet interventions yield only mixed success. Smokers often smoke and crave cigarettes in social settings. Public health research emphasizes social factors in smoking, and clinical studies point to the need to better understand disrupted relationship dynamics when a romantic partner or friend quits. Thus, it is striking that nearly all lab research (testing causal relations) on smoking and craving tests smokers in isolation. This neglect of social factors extends to quitting practices. Even on the most respected websites, the “social” advice for quitting offers fairly simplistic and incomplete tips that fail to consider subtle yet powerful challenges that quitting may create for smoking friends and romantic partners. Further, there is no evidence regarding how social factors exacerbate the altered smoking-related decision-making that accompanies craving, thus raising the likelihood of smoking. To develop a comprehensive understanding of the factors and processes that maintain smoking and increase relapse risk, basic experimental research that integrates social processes into existing paradigms focusing on pharmacologic and (individual) psychological aspects of addiction is needed. This basic experimental study with humans (BESH) application addresses targeted NCI Behavioral Research Program priorities focused on leveraging research on dyadic processes to examine health-related behaviors such as smoking cessation. Integrating theory and research derived from three disciplines rarely applied to smoking (experimental social psychology with a focus on dyadic processes, affective science, cognition), the project will offer a multimodal analysis of craving and smoking in two social contexts relevant to smoking (friendships, romantic couples). This project will use innovative measures of affect (e.g., an urge pressure dynamometer, speech volume, Facial Action Coding System) and decision-making to test theoretically-derived processes (e.g., shared reality, motivated reasoning, emotional contagion) that may help explain the challenges linked to quitting when rewarding social aspects of smoking are lost. The project will elucidate why some smokers may struggle managing relationships when quitting, and why social interventions may be most useful for a subset of smokers. In both a friends study and a couples study, abstinent daily and nondaily smokers will be recruited. The friends study will test the impact of a friend’s presence on cue-elicited craving, with a focus on shared craving states, and the couples study will target effects of mutual smoking versus unilateral smoking on critical social interactions and relationship perceptions thought to raise obstacles to quitting. This project will test important social-cognitive and socio- emotional mechanisms underlying craving and smoking that may identify hidden social motives for smoking that must be integrated into biopsychosocial smoking treatment. Regardless of outcome, this work will provide valuable data on emotional and cognitive processes experienced in social settings during craving and smoking.", "keywords": [ "Acoustics", "Address", "Affect", "Affective", "American", "Behavioral Research", "Cancer Etiology", "Cessation of life", "Cigarette", "Clinical", "Clinical Research", "Code", "Cognition", "Cognitive", "Couples", "Cues", "Data", "Decision Making", "Discipline", "Disclosure", "Electronic cigarette", "Emotional", "Emotions", "Event", "Face", "Friends", "Friendships", "Future", "Goals", "Health", "Health behavior", "Human", "Individual", "Intervention", "Investigation", "Language", "Link", "Malignant Neoplasms", "Measures", "Methodology", "Methods", "Modeling", "Monitor", "Nicotine", "Nicotine Dependence", "Outcome", "Patient Self-Report", "Perception", "Persons", "Pharmaceutical Preparations", "Play", "Preventable cancer cause", "Process", "Public Health", "Reporting", "Research", "Rewards", "Role", "Science", "Smiling", "Smoke", "Smoker", "Smoking", "Smoking treatment", "Social Environment", "Social Interaction", "Social Processes", "Social Psychology", "Speech", "Subgroup", "Testing", "Tobacco", "Treatment Efficacy", "Work", "addiction", "biopsychosocial", "cigarette craving", "cigarette smoking", "cognitive process", "contagion", "craving", "experience", "experimental study", "heuristics", "innovation", "insight", "member", "mortality", "multimodality", "neglect", "novel", "pharmacologic", "premature", "pressure", "prevent", "programs", "psychologic", "public health research", "recruit", "relapse risk", "smoking cessation", "smoking cue", "social", "social factors", "social interventions", "social relationships", "success", "theories", "web site" ], "approved": true } }, { "type": "Grant", "id": "15770", "attributes": { "award_id": "1R21AI194218-01", "title": "Genomic Surveillance of Mpox through the Development of a Wastewater Intelligence Model and Data Analytics Platform", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32841, "first_name": "JANE M", "last_name": "KNISELY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-07", "end_date": "2027-07-31", "award_amount": 416625, "principal_investigator": { "id": 32842, "first_name": "Edwin C.", "last_name": "Oh", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2638, "ror": "", "name": "UNIVERSITY OF NEVADA LAS VEGAS", "address": "", "city": "", "state": "NV", "zip": "", "country": "United States", "approved": true }, "abstract": "A critical challenge in pandemic preparedness is the rapid identification of viral outbreak sources and tracking mutations that lead to new variants. Current public health surveillance methods, relying on resource-intensive laboratory testing of patient specimens, often yield incomplete data due to underreporting. The recent mpox outbreak in the Democratic Republic of the Congo—with over 22,000 suspected cases since January 2023 and the emergence of a new strain (clade 1b)—underscores the need for more effective surveillance tools. To address these limitations, we and others have developed wastewater approaches to screen municipal sewage for viral levels and variants. This method capitalizes on the shedding of pathogens like SARS-CoV-2 and mpox into sewer systems through bodily fluids, providing a comprehensive, real-time snapshot of community infection levels and viral evolution. Over the last five years, our team has built and implemented a comprehensive wastewater COVID-19 surveillance program that includes a community engagement responsive element and serves 2.4 million residents and 50 million annual tourists in Southern Nevada. In Summer 2022, we adapted this program to pilot a study tracking the clade IIb mpox outbreak in Las Vegas. Building on these achievements and developing novel reagents for clades I and II, we have a time-sensitive opportunity to test our central hypothesis: that enhanced wastewater surveillance, coupled with new computational tools, can enable rapid detection of mpox variants from both clades, facilitate assessment of antiviral drug efficacy, and inform strategic prioritization of vaccination sites. This high-risk, high-reward proposal extends our previous successful approaches with SARS-CoV-2, influenza, and drug use in wastewater, potentially breaking new ground in mpox research. Our proposal directly responds to the 2022 and 2024 mpox public health emergency of international concern declarations and aligns with NIAID's 2024 mpox research agenda. The identification of even a single mpox outbreak or treatment-resistant strain through our wastewater studies would significantly advance innovative research in genomic epidemiology and public health surveillance, potentially transforming our approach to managing emerging infectious diseases.", "keywords": [ "2019-nCoV", "Achievement", "Address", "Anti-viral Agents", "Area", "Biological Sciences", "Body Fluids", "COVID-19 surveillance", "Clinical", "Communities", "Coupled", "DNA", "Data", "Data Analytics", "Databases", "Democratic Republic of the Congo", "Detection", "Development", "Disease Outbreaks", "Dose", "Drug usage", "Early Diagnosis", "Effectiveness", "Elements", "Emerging Communicable Diseases", "Ensure", "Evolution", "Genome", "Genomics", "Hour", "Human", "Individual", "Infection", "Influenza", "Intelligence", "International", "Intervention", "Laboratories", "Linear Regressions", "Location", "Methods", "Modeling", "Monitor", "Monkeypox", "Monkeypox virus", "Municipalities", "Mutation", "National Institute of Allergy and Infectious Disease", "Patients", "Pilot Projects", "Plants", "Population Surveillance", "Public Health", "Reagent", "Research", "Resources", "SARS-CoV-2 genome", "SARS-CoV-2 variant", "Sampling", "Sewage", "Site", "Source", "Specimen", "Surveillance Methods", "Surveillance Program", "System", "Testing", "Time", "Vaccination", "Vaccines", "Variant", "Viral", "analysis pipeline", "clinical sequencing", "community engagement", "computational pipelines", "computerized tools", "drug efficacy", "emerging pathogen", "genome sequencing", "genomic data", "genomic epidemiology", "genomic variation", "health equity promotion", "high reward", "high risk", "innovation", "insight", "novel", "pandemic preparedness", "pathogen", "programs", "public health emergency", "rapid detection", "resistant strain", "response", "southern nevada", "tool", "transmission process", "urban area", "viral DNA", "viral detection", "viral outbreak", "wastewater samples", "wastewater surveillance", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "15752", "attributes": { "award_id": "1DP2CA311214-01", "title": "Harnessing natural killer cells for cellular immunotherapy against solid tumors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32810, "first_name": "LILLIAN S", "last_name": "KUO", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-06", "end_date": "2028-07-31", "award_amount": 1457050, "principal_investigator": { "id": 32811, "first_name": "Wilfredo F", "last_name": "Garcia-Beltran", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2623, "ror": "", "name": "MASSACHUSETTS GENERAL HOSPITAL", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite recent advances in cancer therapy, cancer remains the second leading cause of death in the United States. The field of cancer immunotherapy has evolved to meet this challenge, but there is an ongoing need for treating metastatic and treatment-resistant solid tumors, particularly those of lung, breast, prostate, and colorectal origin. Cellular immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, have shown success in treating blood cancers. However, they remain ineffective against solid tumors, and are often fraught with inherent toxicities such as cytokine release syndrome and attack of healthy tissues. In light of these challenges, this proposal aims to harness natural killer (NK) cells, which have broad anti-tumor activity and a superior safety profile, to generate CAR NK-cell therapy as an effective immunotherapy against solid tumors. CAR NK-cell therapy has recently shown remarkable success against blood cancers but remains challenging for use in solid tumors. The tumor microenvironment employs immune-evasive mechanisms to subvert NK-cell killing and limits their infiltration and survival. Our research proposal will address these obstacles by leveraging high-throughput, sequencing-based functional screens and innovative synthetic biology approaches that will shed light on fundamental NK-cell biology and enhance CAR NK-cell infiltration and killing of solid tumors. We will implement a genome-wide CRISPR screen in primary human NK cells to identify negative regulators (‘innate immune checkpoints’) of NK-cell cytotoxicity. Subsequently, we will identify homing and survival signals in tumor- infiltrating immune cells by mining single-cell RNA-sequencing databases. We will then introduce these genes into NK cells to enhance their infiltration and survival in in-vitro and in-vivo models of the tumor microenvironment. Finally, we will perform a high-throughput CARpool screen to simultaneously assess hundreds of NK cell-tailored CARs designed with native NK cell-receptor signaling machinery to maximize CAR NK-cell functioning. In summary, this proposed research introduces several innovative approaches to study fundamental NK-cell biology and engineer NK-cell based immunotherapies against solid tumors. Our project is poised to uncover new targets in NK cells for 'innate immune checkpoint blockade' as well as create the next-generation of CAR NK- cell therapy for treating metastatic and treatment-resistant cancers. Ultimately, we will establish a pipeline of technologies that can be applied to many cancer types in order to broaden the scope of immunotherapies against cancer and transform patient care to mitigate the devastating impact of this disease.", "keywords": [ "Biomedical Engineering", "Breast", "CAR T cell therapy", "CRISPR screen", "Cancer Etiology", "Cause of Death", "Cell Physiology", "Cell Therapy", "Cells", "Cellular biology", "Cellular immunotherapy", "Cessation of life", "Colorectal", "Colorectal Cancer", "Disease", "Effectiveness", "Genes", "Goals", "Hematopoietic Neoplasms", "Homing", "Human", "Immune", "Immune Evasion", "Immunotherapy", "In Vitro", "Infiltration", "Light", "Lung", "Malignant Breast Neoplasm", "Malignant Neoplasms", "Malignant neoplasm of lung", "Malignant neoplasm of prostate", "Methods", "Mining", "Molecular and Cellular Biology", "NK cell therapy", "Natural Killer Cells", "Patient Care", "Patients", "Prostate", "Quality of life", "Receptor Signaling", "Research", "Research Proposals", "Resistance", "Safety", "Signal Transduction", "Solid Neoplasm", "Technology", "Tissues", "Toxic effect", "Tumor-infiltrating immune cells", "United States", "cancer immunotherapy", "cancer therapy", "cancer type", "cell killing", "chimeric antigen receptor", "chimeric antigen receptor natural killer cells", "cytokine release syndrome", "cytotoxicity", "design", "engineered NK cell", "genome-wide", "immune checkpoint blockade", "improved", "in vivo Model", "innate immune checkpoint", "innovation", "molecular sequence database", "next generation", "refractory cancer", "single-cell RNA sequencing", "success", "synthetic biology", "tumor", "tumor microenvironment" ], "approved": true } }, { "type": "Grant", "id": "15747", "attributes": { "award_id": "1R13CA301746-01", "title": "2025 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32802, "first_name": "CHRISTINA DAWN", "last_name": "GEORGE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-06", "end_date": "2026-07-31", "award_amount": 8000, "principal_investigator": { "id": 32803, "first_name": "Scott M.", "last_name": "Dehm", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2618, "ror": "", "name": "GORDON RESEARCH CONFERENCES", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "The Gordon Research Conference (GRC) and the associated Gordon Research Seminar (GRS) on “Hormone-Dependent Cancers” build on the success of five prior GRC conferences on this topic in 2013, 2015, 2017, 2019, and 2023. No meeting was held 2021 due to COVID-19 restrictions. The 2025 GRC “Hormone-Dependent Cancers: A Place in Time, from the Global to the Cellular, the Significance of Environment and Tumor Dynamics on Disease Progression” will provide the stimulating and engaging format for interaction and fruitful exchange of knowledge to allow new ideas, collaborations, and projects to develop, with the ultimate goal to decrease suffering and casualties from the disease. We will cover varied perspectives on hormone-dependent cancers through the voices of early stage and experienced investigators, as well as investigators from academia and industry. The GRS entitled “Next-Generation Approaches in Basic Science and Clinical Data Integration” will precede the GRC, and is specifically geared towards early-career scientists (ECS) including graduate students, postdoctoral fellows, and clinical fellows. Leading national and international speakers will present research that represents the entire spectrum, from basic biology to clinical application of their biological findings. The focus of the meeting is hormone-dependent cancers, with an emphasis on breast and prostate cancers, since 75% of all breast cancers and all prostate cancers are deemed hormone-dependent. The presentations will be divided among a total of 9 sessions: Keynote Session 1: Advances in Therapeutic Targeting; Session 2: Breast and Prostate Metastasis; Session 3 How Important is Location?; Session 4: Nuclear Receptors, Steroid Sisters, and Orphan Brothers; Session 5: Dynamic Actions, Epi-Genomic and Epi-Transcriptomic Plasticity with Disease Progression; Session 6: Immunology, Metabolism, and Next Generation Approaches to Targeted Treatment Strategies; Session 7: Hormone-Dependent Cancer Global and Population Outcomes; Session 8: Artificial Intelligence (AI), revolutionizing translational research; Keynote Session 2: Key Areas and Questions in Hormones & Cancer. The overall goal of the 2025 GRC/GRS is to encourage the stimulation of new projects and scientific collaborations across multiple disciplines and through informal means. With the discussion of state-of-the-art research and industry perspectives on hormone-dependent cancers, we hope to foster new discoveries, create improved therapies targeting these cancers and ultimately, improve patient outcomes.", "keywords": [ "Academia", "Address", "Area", "Artificial Intelligence", "Awareness", "Basic Science", "Biological", "Biology", "Breast", "Brothers", "COVID-19", "Clinical", "Clinical Data", "Clinical Research", "Collaborations", "Data", "Dedications", "Development", "Discipline", "Disease", "Disease Progression", "Environment", "Fostering", "Goals", "Growth", "Health Care", "Heterogeneity", "Hormones", "Hour", "Immunology", "Industry", "International", "Knowledge", "Laboratory Finding", "Location", "Malignant Breast Neoplasm", "Malignant Neoplasms", "Malignant neoplasm of prostate", "Mentors", "Mentorship", "Metabolism", "Methods", "Neoplasm Metastasis", "Nuclear Receptors", "Orphan", "Outcome", "Patient-Focused Outcomes", "Population", "Postdoctoral Fellow", "Prostate", "Publishing", "Research", "Research Personnel", "Role", "Running", "Scientist", "Senior Scientist", "Sister", "Steroids", "Students", "Time", "Translational Research", "Update", "Voice", "Work", "anti-cancer research", "career", "career development", "clinical application", "clinical development", "clinical practice", "data integration", "design", "epigenomics", "epitranscriptomics", "experience", "global health", "graduate student", "health care disparity", "improved", "innovation", "interdisciplinary collaboration", "meetings", "next generation", "novel strategies", "novel therapeutics", "patient engagement", "patient population", "peer", "posters", "skills", "success", "symposium", "targeted cancer therapy", "targeted treatment", "therapeutic target", "translational pipeline", "treatment strategy", "tumor", "tumor microenvironment" ], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1405, "count": 14046 } } }